Accelerated aging in normal breast tissue of women with breast cancer.
Accelerated aging
DNA methylation
Outliers
Predicted age
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
22 05 2021
22 05 2021
Historique:
received:
29
12
2020
accepted:
26
04
2021
entrez:
23
5
2021
pubmed:
24
5
2021
medline:
1
1
2022
Statut:
epublish
Résumé
DNA methylation alterations have similar patterns in normal aging tissue and in cancer. In this study, we investigated breast tissue-specific age-related DNA methylation alterations and used those methylation sites to identify individuals with outlier phenotypes. Outlier phenotype is identified by unsupervised anomaly detection algorithms and is defined by individuals who have normal tissue age-dependent DNA methylation levels that vary dramatically from the population mean. We generated whole-genome DNA methylation profiles (GSE160233) on purified epithelial cells and used publicly available Infinium HumanMethylation 450K array datasets (TCGA, GSE88883, GSE69914, GSE101961, and GSE74214) for discovery and validation. We found that hypermethylation in normal breast tissue is the best predictor of hypermethylation in cancer. Using unsupervised anomaly detection approaches, we found that about 10% of the individuals (39/427) were outliers for DNA methylation from 6 DNA methylation datasets. We also found that there were significantly more outlier samples in normal-adjacent to cancer (24/139, 17.3%) than in normal samples (15/228, 5.2%). Additionally, we found significant differences between the predicted ages based on DNA methylation and the chronological ages among outliers and not-outliers. Additionally, we found that accelerated outliers (older predicted age) were more frequent in normal-adjacent to cancer (14/17, 82%) compared to normal samples from individuals without cancer (3/17, 18%). Furthermore, in matched samples, we found that the epigenome of the outliers in the pre-malignant tissue was as severely altered as in cancer. A subset of patients with breast cancer has severely altered epigenomes which are characterized by accelerated aging in their normal-appearing tissue. In the future, these DNA methylation sites should be studied further such as in cell-free DNA to determine their potential use as biomarkers for early detection of malignant transformation and preventive intervention in breast cancer.
Sections du résumé
BACKGROUND
DNA methylation alterations have similar patterns in normal aging tissue and in cancer. In this study, we investigated breast tissue-specific age-related DNA methylation alterations and used those methylation sites to identify individuals with outlier phenotypes. Outlier phenotype is identified by unsupervised anomaly detection algorithms and is defined by individuals who have normal tissue age-dependent DNA methylation levels that vary dramatically from the population mean.
METHODS
We generated whole-genome DNA methylation profiles (GSE160233) on purified epithelial cells and used publicly available Infinium HumanMethylation 450K array datasets (TCGA, GSE88883, GSE69914, GSE101961, and GSE74214) for discovery and validation.
RESULTS
We found that hypermethylation in normal breast tissue is the best predictor of hypermethylation in cancer. Using unsupervised anomaly detection approaches, we found that about 10% of the individuals (39/427) were outliers for DNA methylation from 6 DNA methylation datasets. We also found that there were significantly more outlier samples in normal-adjacent to cancer (24/139, 17.3%) than in normal samples (15/228, 5.2%). Additionally, we found significant differences between the predicted ages based on DNA methylation and the chronological ages among outliers and not-outliers. Additionally, we found that accelerated outliers (older predicted age) were more frequent in normal-adjacent to cancer (14/17, 82%) compared to normal samples from individuals without cancer (3/17, 18%). Furthermore, in matched samples, we found that the epigenome of the outliers in the pre-malignant tissue was as severely altered as in cancer.
CONCLUSIONS
A subset of patients with breast cancer has severely altered epigenomes which are characterized by accelerated aging in their normal-appearing tissue. In the future, these DNA methylation sites should be studied further such as in cell-free DNA to determine their potential use as biomarkers for early detection of malignant transformation and preventive intervention in breast cancer.
Identifiants
pubmed: 34022936
doi: 10.1186/s13058-021-01434-7
pii: 10.1186/s13058-021-01434-7
pmc: PMC8140515
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Subventions
Organisme : Susan G. Komen
ID : PDF17479825
Pays : United States
Organisme : W.W.Smith Charitable Trust
ID : C1908
Références
Genes Dev. 2011 May 15;25(10):1010-22
pubmed: 21576262
BMC Cancer. 2015 Oct 29;15:816
pubmed: 26510686
Epigenetics. 2012 Dec 1;7(12):1368-78
pubmed: 23075513
BMC Bioinformatics. 2016 Apr 22;17:178
pubmed: 27103033
Breast Cancer Res. 2017 Jul 10;19(1):81
pubmed: 28693600
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
Am J Hum Genet. 1994 Oct;55(4):666-77
pubmed: 7942844
Epigenetics. 2014 Feb;9(2):268-75
pubmed: 24196486
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Clin Epigenetics. 2018 Aug 29;10(1):112
pubmed: 30157950
Mol Cell. 2018 Sep 20;71(6):882-895
pubmed: 30241605
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Genes Dev. 2002 Jan 1;16(1):6-21
pubmed: 11782440
Cancer Res. 1998 Dec 1;58(23):5489-94
pubmed: 9850084
Nat Rev Cancer. 2011 Sep 23;11(10):726-34
pubmed: 21941284
Bioinformatics. 2013 Jan 15;29(2):189-96
pubmed: 23175756
Nat Rev Genet. 2005 Aug;6(8):597-610
pubmed: 16136652
Nat Rev Genet. 2018 Jun;19(6):371-384
pubmed: 29643443
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
J Clin Invest. 2014 Jan;124(1):24-9
pubmed: 24382386
Nat Commun. 2016 Jan 29;7:10478
pubmed: 26823093
Nat Genet. 1994 Aug;7(4):536-40
pubmed: 7951326
BMC Genomics. 2012 Oct 30;13:570
pubmed: 23107584
Epigenetics. 2016 Aug 2;11(8):614-24
pubmed: 27302749
Nat Commun. 2017 Sep 14;8(1):539
pubmed: 28912502
Epigenomics. 2016 May;8(5):705-19
pubmed: 27104983
Mol Oncol. 2015 Mar;9(3):555-68
pubmed: 25468711
Methods Mol Biol. 2018;1708:247-265
pubmed: 29224148
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Breast Cancer Res Treat. 2015 Feb;149(3):767-79
pubmed: 25636590
Genome Biol. 2015 May 13;16:96
pubmed: 25968125
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
Anticancer Res. 2014 Mar;34(3):1071-7
pubmed: 24596345
Breast Cancer Res Treat. 2017 Jul;164(1):209-219
pubmed: 28364215
Nat Genet. 2006 Dec;38(12):1378-85
pubmed: 17072317
Magn Reson Imaging. 2005 May;23(4):591-9
pubmed: 15919606
Adv Cancer Res. 2019;142:1-22
pubmed: 30885359
EBioMedicine. 2018 May;31:243-252
pubmed: 29735413